ArriVent BioPharma, Inc.
AVBPNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $799.32M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $11.36$35.83
- Volume (live)
- -
- Avg. volume (3M)
- 1.62M
ArriVent BioPharma (AVBP) Stock Price & Financial Analysis
ArriVent BioPharma Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $16.49 - $17.23 |
|---|---|
| 52-Week High | $35.83 |
| 52-Week Low | $11.36 |
| Open | $16.86 |
| Volume (last close) | 1.33M |
| Average Volume (3M) | 1.62M |
| 50-Day MA | $27.90 |
|---|---|
| 200-Day MA | $27.15 |
| 1-Year Change | −13.94% |
| Market Cap | 799.32M |
|---|---|
| Shares Outstanding | 47.61M |
| Price to Book (P/B) | 2.18 |
| EV/EBITDA | -3.74 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
ArriVent BioPharma at a Glance
As of the Oct 16, 2026 close, ArriVent BioPharma (AVBP) has a market capitalization of $799.32M.
As of its latest reported balance sheet, it holds $154.68M in cash and securities against $351.00K of debt, a net cash position of $154.33M.
ArriVent BioPharma does not currently pay a dividend.
The share price is down 13.9% over the past year. At $16.66 (the Oct 16, 2026 close) it sits within its 52-week range of $11.36 to $35.83, below its 200-day moving average of $27.15.
Based on 11 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $28.36, 70.2% above the Oct 16, 2026 close.
Frequently Asked Questions About ArriVent BioPharma
What is the current stock price for AVBP?
As of the Oct 16, 2026 close, AVBP stock trades at $16.66. The 52-week range is $11.36–$35.83, with a day range of $16.48–$17.23.
What is the P/E ratio for AVBP?
The P/E ratio (Price-to-Earnings) for AVBP is shown in the Key Statistics section. This valuation metric helps compare ArriVent BioPharma, Inc. to industry peers.
Does AVBP pay dividends?
ArriVent BioPharma does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AVBP?
Based on ratings from 11 professional analysts over the last 90 days, the consensus for AVBP is Buy. The average 12-month price target is $28.36, a 70.2% upside from the Oct 16, 2026 close of $16.66.
What is the market cap of AVBP?
As of the Oct 16, 2026 close, ArriVent BioPharma's market capitalization is $793.1M, classifying it as a small-cap company. ArriVent BioPharma operates in the Healthcare sector within the Biotechnology industry.